• Andrew McKeon, Eugenia Martinez-Hernandez, Eric Lancaster, Joseph Y Matsumoto, Robert J Harvey, Kathleen M McEvoy, Sean J Pittock, Vanda A Lennon, and Josep Dalmau.
• Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
• JAMA Neurol. 2013 Jan 1;70(1):44-50.

ObjectivesTo determine whether glycine receptor α1 subunit-specific autoantibodies (GlyRα1-IgG) occur in a broader spectrum of brainstem and spinal hyperexcitability disorders than the progressive encephalomyelitis with rigidity and myoclonus phenotype recognized to date, and to ascertain disease specificity.DesignRetrospective, case-control study.SettingsMayo Clinic, Rochester, Minnesota, and University of Barcelona, Spain.PatientsEighty-one patients with stiff-man syndrome phenotype, 80 neurologic control subjects, and 20 healthy control subjects.InterventionGlycine receptor α1-transfected cells to test serum or cerebrospinal fluid from cases and control subjects.Main Outcome MeasuresFrequency of GlyRα1-IgG positivity among stiff-man syndrome phenotype cases and control subjects. Comparison of GlyRα1-IgG seropositive and seronegative cases.ResultsSeropositive cases (12% of cases) included 9 with stiff-man syndrome (4 classic; 5 variant; 66% were glutamic acid decarboxylase 65-IgG positive) and 1 with progressive encephalomyelitis with rigidity and myoclonus. Immunotherapy responses were noted more frequently in GlyRα1-IgG-positive cases (6 of 7 improved) than in seronegative cases (7 of 25 improved; P= .02). The single seropositive control patient had steroid-responsive vision loss and optic atrophy with inflammatory cerebrospinal fluid.ConclusionsGlycine receptor α1-IgG aids identification of autoimmune brainstem/spinal cord hyperexcitability disorders and may extend to the glycinergic visual system.

32 keywords...

hide…